Results 71 to 80 of about 4,521 (193)

Filgotinib to Treat Acute Severe Refractory Ulcerative Colitis: A Case Report and Review of the Literature

Case Reports in Gastroenterology
Introduction: Acute severe ulcerative colitis (ASUC) is a serious complication affecting 9%–15% of patients with UC within 3 months of diagnosis and up to 28% of patients during the course of the disease.
G. Vespere, S. Sedda, P. Madonna, Roberta Abete, A. D'Avino, Manuela Maione, M. Lugarà, Antonietta Tazza, Franco Scaldaferri, Giuseppe Vitiello, Leonardo De Luca   +10 more
semanticscholar   +1 more source

Effects of hypnotic bromovalerylurea on microglial BV2 cells [PDF]

, 2017
Ehime University (愛媛大学)博士(医学)doctoral ...
KAWASAKI, Shun, 川崎, 俊
core  

Patients with diffuse idiopathic skeletal hyperostosis have an increased burden of thoracic aortic calcifications [PDF]

, 2022
OBJECTIVES: DISH has been associated with increased coronary artery calcifications and incident ischaemic stroke. The formation of bone along the spine may share pathways with calcium deposition in the aorta.
Asselbergs, FW, Bots, ML, De Borst, GJ, De Jong, PA, De Jong, PA, Emmelot, MH, Foppen, W, Geerlings, MI, Harlianto, NI, Hol, ME, Kappelle, LJ, Leiner, T, Lely, AT, Mohamed Hoesein, FAA, Nathoe, HM, Ruigrok, YM, Van Der Kaaij, NP, Van Der Veen, PH, Van Ginneken, B, Verhaar, MC, Verlaan, JJ, Visseren, FLJ, Westerink, J, Wittenberg, R   +23 more
core  

Correction to: Filgotinib: First Approval [PDF]

Drugs, 2021
Dhillon, Sohita, Keam, Susan J.
openaire   +1 more source

Dynamics of Serum Cytokines and Chemokines in Patients With Idiopathic Multicentric Castleman Disease: From a Phase Ib Investigator-Initiated Trial of Filgotinib

Cureus
Background Idiopathic multicentric Castleman disease (iMCD) is a chronic inflammatory condition for which Janus kinase (JAK) inhibition has been hypothesized to be a potential treatment.
S. Fukui, R. Sumiyoshi, T. Koga, N. Hosogaya, Sawana Narita, S. Morimoto, Hiroshi Yano, Atsushi Katsube, S. Yano, Y. Masaki, Shinichiro Tsunoda, S. Sato, Kiyoshi Migita, A. Kawakami   +13 more
semanticscholar   +1 more source

Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE [PDF]

, 2022
OBJECTIVES: Juvenile-onset systemic lupus erythematosus (jSLE) affects 15–20% of lupus patients. Clinical heterogeneity between racial groups, age groups and individual patients suggests variable pathophysiology.
Beresford, M, Charras, A, Ciurtin, Coziana, Egbivwie, N, Haldenby, S, Hedrich, C, Olohan, L, Smith, Eve   +7 more
core  

Filgotinib bei Colitis ulcerosa: ein Review

Journal für Gastroenterologische und Hepatologische Erkrankungen
ZusammenfassungColitis ulcerosa ist eine chronisch entzündliche Darmerkrankung mit Befall des Kolons. Die häufigsten Symptome sind blutige und schleimige Durchfälle, Stuhldrang sowie abdominelle Schmerzen. Diese Symptome stellen für die Betroffenen oft eine wesentliche gesundheitliche Beeinträchtigung dar.Filgotinib ist ein Medikament, das in oraler ...
Blesl, Andreas, Novacek, Gottfried, Reinisch, Walter, Kienbauer, Melanie, Platzer, Reingard, Wolzt, Michael, Koch, Robert, Högenauer, Christoph, Ribarics, Reiner, Moschen, Alexander   +9 more
openaire   +2 more sources

Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial [PDF]

IMPORTANCE: Noninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options. OBJECTIVE: To assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment ...
Barchuk, William T, Besuyen, Robin, Chu, David S, Dacey, Mark S, Dick, Andrew D, Faia, Lisa J, Genovese, Mark C, Grewal, Dilraj S, Guo, Ying, Nguyen, Quan Dong, Rosenbaum, James T, Scales, David K, Shah, Rajiv E, Sharma, Sumit, Srivastava, Sunil K, Suhler, Eric B, Watkins, Timothy R   +16 more
core  

Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.

, 2018
Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage and bone destruction and several systemic features.
Barbieri, L, de Paulis, A, Liccardo, B, Lobasso, A, Rivellese, F, Rossi, FW   +5 more
core   +2 more sources

Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data [PDF]

The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib, has significantly widened the therapeutic options for patients with inflammatory bowel disease (IBD).
Alfredo Papa, Angelo Del Gaudio, Antonio Gasbarrini, Franco Scaldaferri, Gaetano Coppola, Jacopo Iaccarino, Loris Riccardo Lopetuso, Lucrezia Laterza, Pierluigi Puca, Stefania Colantuono, Valentina Blasi   +10 more
core   +1 more source